UNS 0.00% 0.5¢ unilife corporation

Sanofi up 3%

  1. 52 Posts.
    lightbulb Created with Sketch. 2
    R&D Update
    Regulatory updates since the publication of the third-quarter 2014 results on October 28, 2014 include the following:
    • In January, the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for Praluent™ (alirocumab, in collaboration with Regeneron). In January, the U.S. Food and Drug Administration (FDA) has accepted for priority review the biologics license application (BLA) for Praluent™. Praluent™ is an investigational monoclonal antibody targeting PCSK9 that is intended for the treatment of patients with hypercholesterolemia.
    • In January, the rolling submission for Dengue vaccine was initiated in several endemic countries in Asia.
    • In December, Fluzone® Quadrivalent ID vaccine (a four-strain influenza vaccine which uses a microinjection system for intradermal delivery) was approved in the U.S.
    • In November, the FDA approved the supplemental biologics license application (sBLA) for Fluzone® High-Dose (Influenza Vaccine) to include efficacy data in the Prescribing Information. These data demonstrate that Fluzone® High-Dose vaccine provided improved protection against influenza compared to standard-dose Fluzone® vaccine (trivalent intramuscular formulation) in adults 65 years of age and older.
    • In November, the FDA granted Breakthrough Therapy designation for dupilumab, an investigational monoclonal antibody that blocks IL-4 and IL-13, two cytokines required for the Th2 immune response, for the treatment of adults with moderate-to-severe atopic dermatitis that are not adequately controlled with topical prescription therapy and/or for whom these treatments are not appropriate.
    • In November, the FDA approved Lemtrada® (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis and who have had an inadequate response to two or more drugs.
 
watchlist Created with Sketch. Add UNS (ASX) to my watchlist
Currently unlisted public company
(20min delay)
Last
0.5¢
Change
0.00(0.00%)
Mkt cap $1.898M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0
UNS (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.